# Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

> **NCT02315443** · PHASE3 · COMPLETED · sponsor: **NoNO Inc.** · enrollment: 532 (actual)

## Conditions studied

- Acute Cerebral Ischemia

## Interventions

- **DRUG:** Nerinetide (NA-1)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02315443
- **Lead sponsor:** NoNO Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-26
- **Primary completion:** 2023-03-27
- **Final completion:** 2023-03-27
- **Target enrollment:** 532 (ACTUAL)
- **Last updated:** 2023-05-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315443, "Field Randomization of Nerinetide (NA-1) Therapy in Early Responders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02315443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*